TFR Capital LLC. Buys 2,261 Shares of Johnson & Johnson (NYSE:JNJ)

TFR Capital LLC. increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 104.6% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,423 shares of the company's stock after acquiring an additional 2,261 shares during the period. TFR Capital LLC.'s holdings in Johnson & Johnson were worth $734,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. WealthTrak Capital Management LLC acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $29,000. Conquis Financial LLC acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $33,000. Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $38,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Raymond James Financial lowered their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Morgan Stanley reaffirmed an "underperform" rating on shares of Johnson & Johnson in a research report on Thursday. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average price target of $171.00.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $156.87 on Monday. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The firm has a market capitalization of $377.44 billion, a price-to-earnings ratio of 17.45, a PEG ratio of 2.14 and a beta of 0.41. The business has a 50-day simple moving average of $153.75 and a 200 day simple moving average of $154.55. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.